Ozempic vs Mounjaro (Semaglutide vs Tirzepatide): What the Head-to-Head Trials Show

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

What each drug actually is

Both are weekly injectable peptides, but different classes. Semaglutide activates the GLP-1 receptor; it’s sold as Ozempic for type 2 diabetes and Wegovy for weight management (and Wegovy now also carries a cardiovascular-risk-reduction indication) FDA. Tirzepatide activates two receptors — GIP and GLP-1 — and is sold as Mounjaro for diabetes and Zepbound for weight management (and obstructive sleep apnea in obesity) FDA Wang 2024. The practical point: the brand names are marketing; there are really just two molecules, and they are not interchangeable.

Weight loss: the head-to-head

The only fair apples-to-apples comparison for weight is a direct trial. SURMOUNT-5 randomised 751 adults with obesity (without diabetes) to tirzepatide or semaglutide at their maximum tolerated doses for 72 weeks. Tirzepatide was superior: −20.2% body weight versus −13.7% for semaglutide (P<0.001), with greater waist reduction too SURMOUNT-5 2025. The single-drug obesity trials line up with that ranking — tirzepatide reached up to ~21% in SURMOUNT-1 SURMOUNT-1 and semaglutide ~15% in STEP-1 STEP-1 — but those were separate placebo trials in different people, so you can’t simply line up their numbers; SURMOUNT-5 is the valid comparison.

Blood sugar (type 2 diabetes)

There’s also a direct diabetes trial. SURPASS-2 compared tirzepatide against semaglutide (on top of metformin) in 1,879 adults with type 2 diabetes over 40 weeks. All tirzepatide doses produced greater A1c reduction (e.g. −2.30 vs −1.86 points; P<0.001) and more weight loss SURPASS-2. So on the two things these drugs are designed to do — lower weight and lower blood sugar — the head-to-head data favour tirzepatide on average SURMOUNT-5 2025 SURPASS-2.

Heart protection: semaglutide’s edge

Here the picture flips. The strongest cardiovascular-outcome evidence belongs to semaglutide: in SELECT (17,604 adults with overweight/obesity and established heart disease, no diabetes), semaglutide cut major adverse cardiovascular events by about 20% (hazard ratio 0.80) SELECT 2023. Tirzepatide’s cardiovascular-outcomes trial compared it against another GLP-1 drug (dulaglutide) and showed non-inferiority — it did not demonstrate superiority on hard cardiac endpoints, and it was never tested head-to-head against semaglutide for heart outcomes SURPASS-CVOT 2025. So if proven cardiac-event reduction is the priority, semaglutide currently has the better-established data SELECT 2023 SURPASS-CVOT 2025.

Side effects and safety

Both share the same dominant profile: gastrointestinal — nausea, vomiting, diarrhoea, constipation — mostly mild-to-moderate and concentrated during the dose build-up SURMOUNT-5 2025 SURPASS-2. In the head-to-head, GI side effects leading to stopping were a little more common with semaglutide than tirzepatide SURMOUNT-5 2025. Both also carry, at the label level, a boxed warning about thyroid C-cell tumours (and are contraindicated with a personal or family history of medullary thyroid cancer or MEN-2), plus risks including pancreatitis and gallbladder disease FDA. These are exactly the reasons they require a prescriber who screens for contraindications and monitors you.

The honest verdict

On the direct evidence, tirzepatide tends to deliver more weight loss and more A1c reduction SURMOUNT-5 2025 SURPASS-2, while semaglutide has the stronger proven heart-protection SELECT 2023. But “more weight loss on average” isn’t the same as “better for you.” The right choice depends on your other conditions, how you tolerate the side effects, what your insurance covers and what you can actually get, and your clinician’s judgment. There is no universal winner here — there’s a best fit for a specific person.

This article is educational journalism, not medical advice. Ozempic, Wegovy, Mounjaro and Zepbound are prescription medicines that require medical supervision, screening, and monitoring; never start, stop, switch, or source them based on an article. Do not buy or “compound” these from gray-market vendors. Talk to a qualified clinician about what’s right for you.

How they're started: the slow-climb dosing schedule

Neither drug is started at its full strength. Both use a multi-month "titration" (a gradual dose climb) precisely because the stomach- and gut-related side effects are worst when the dose jumps too fast. Understanding the schedule explains why people don't see headline weight-loss numbers in week one — and why patience matters.

For weight management, semaglutide (the Wegovy version) follows a fixed five-step climb: 0.25 mg once weekly for the first 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, each held for 4 weeks, reaching the 2.4 mg maintenance dose at around week 16—17 StatPearls 2024. The diabetes version (Ozempic) climbs more gently and tops out lower—typically 0.25 mg, then 0.5, 1.0, and a 2.0 mg maximum, stepped up only as needed for blood-sugar control StatPearls 2024. Tirzepatide starts at 2.5 mg once weekly and rises by 2.5 mg every 4 weeks toward a possible 15 mg ceiling, so reaching the top dose takes roughly five months StatPearls 2024. That is why the SURMOUNT-1 obesity trial used a 20-week escalation before participants settled onto their maintenance dose Jastreboff 2022.

The practical takeaway: these are slow-burn medications by design. A clinician will usually hold you at a lower dose—or pause the climb—if nausea, vomiting, or diarrhoea are intolerable, rather than push to the maximum. The "best" dose is the lowest one that produces the result you need, not automatically the highest available. Both labels also flag that the gut-slowing effect can blunt the absorption of oral contraceptive pills, especially in the first 4 weeks and after each tirzepatide dose increase—so anyone relying on the pill is advised to add a barrier method or switch to a non-oral contraceptive during those windows StatPearls 2024.

What happens when you stop: the regain reality

The single most under-discussed fact about both drugs is what happens after you stop taking them. The current evidence is consistent and sobering: for most people, these are treatments for a chronic condition, not a short course that "cures" it. When the drug comes off, much of the lost weight tends to come back.

The cleanest evidence comes from purpose-built withdrawal trials. In STEP 4, adults first lost weight on semaglutide for 20 weeks, then were randomly assigned to keep taking it or switch to a dummy injection. Over the next 48 weeks, those who continued lost a further ~8% of body weight while those switched to placebo regained ~7%—an estimated 14.8-percentage-point gap between the two paths Rubino 2021. The STEP 1 long-term extension told the same story over a full year off-drug: participants regained roughly two-thirds of the weight they had lost, ending about 5.6% below their starting weight versus the 17.3% loss they had achieved on treatment Wilding 2022.

Tirzepatide behaves the same way. In SURMOUNT-4, people who had already lost substantial weight were randomised to continue tirzepatide or stop. Over the following 52 weeks, the continuers lost an additional ~5.5% while those who stopped regained ~14%—a 19.4-percentage-point difference, and only about 17% of the stoppers held onto most of their loss versus ~90% of those who stayed on the drug Aronne 2024. The lesson is not that the drugs "stop working." It is that they manage an underlying biology (appetite signalling) that reasserts itself once the medication is gone. This is why clinicians increasingly frame the choice as a long-term commitment—ideally paired with durable diet and activity habits—and why suddenly stopping for cost or supply reasons can quietly undo a year of progress. Discuss any plan to pause or stop with the prescriber rather than going it alone.

The muscle-loss question, in proportion

A common worry, amplified online, is that these drugs "eat your muscle." The reality is more nuanced and worth getting right. Any large weight loss—from dieting, surgery, or medication—comes partly from lean tissue, not just fat. The relevant question is the ratio, and whether muscle can be protected.

In a DEXA body-composition sub-analysis of STEP 1, semaglutide cut total fat mass by 19.3% and the more dangerous visceral (around-the-organs) fat by 27.4%, while lean body mass fell by 9.7% Wilding 2021. Crucially, because fat fell faster than lean tissue, the proportion of the body that was lean actually rose by about 3 percentage points Wilding 2021. In other words, body composition improved overall even though some lean mass was lost—and "lean mass" on a DEXA scan includes water and organ tissue, not pure muscle, so the figure overstates true muscle loss. The article does not claim one drug spares muscle better than the other; head-to-head body-composition data remain limited.

What is well established is how to blunt lean-mass loss during any weight loss: resistance (strength) training plus adequate protein. A meta-analysis of caloric-restriction studies in older adults found that adding resistance training prevented about 93.5% of the lean-body-mass loss seen with dieting alone Sardeli 2018. That principle applies directly to GLP-1 users: a few strength sessions a week and a deliberate protein target are the evidence-based way to keep the weight you lose mostly fat. This matters most for older adults, who start with less muscle to spare; anyone over 65 or already frail should raise muscle preservation with their clinician before and during treatment.

Who must be cautious — and who should avoid them

Both drugs share the same hard stop-signs, and both carry a boxed warning—the strongest the regulator issues—about thyroid C-cell tumours seen in rodents (whether this translates to humans is unknown). Each is contraindicated (meaning it must not be used) in anyone with a personal or family history of medullary thyroid carcinoma, a specific thyroid cancer, or the inherited syndrome MEN 2 (multiple endocrine neoplasia type 2), and in anyone who has had a serious allergic reaction to the drug StatPearls 2024 StatPearls 2024.

Beyond those absolutes, several groups need a careful conversation first. Both drugs list pancreatitis (inflammation of the pancreas) as a risk and warrant caution in anyone with a history of it; sudden severe abdominal pain on treatment is an emergency StatPearls 2024. Because they slow stomach emptying, they can worsen severe gastrointestinal disease such as gastroparesis. Rapid weight loss raises the odds of gallstones, and both labels flag gallbladder problems StatPearls 2024. When combined with insulin or a sulfonylurea (older diabetes pills), the risk of low blood sugar rises, so those doses often need reducing StatPearls 2024. Pre-existing diabetic retinopathy can temporarily worsen as blood sugar drops quickly StatPearls 2024.

Finally, neither drug is for use in pregnancy: animal studies show potential fetal harm, and weight loss is not advised while pregnant. Guidance is to stop semaglutide at least two months before a planned pregnancy because it lingers in the body StatPearls 2024. None of this is a reason for fear—tens of millions use these drugs safely—but it is a reason these are prescription medicines requiring a proper medical history, not a casual online purchase. If any of the above applies to you, that is a conversation to have with a clinician before starting.

Wondering about the ‘natural’ alternative? See berberine vs Ozempic.

These drugs do more than weight loss — see what GLP-1s actually do beyond the scale.

References